The management of ductal carcinoma in situ (DCIS) has changed markedly since the mid-1980s with many cases now being treated by breast conserving treatment. The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-17 clearly showed that lumpectomy followed by radiation therapy was more effective than lumpectomy alone in prevention of an invasive tumor in the ipsilateral breast. Tamoxifen has also been reported to prevent tumour recurrences in the ipsilateral breast and second primary tumors in the contralateral breast of women who have undergone lumpectomy and radiation therapy for primary invasive breast cancer. …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.